Dani Bancroft, Author at Labiotech.eu

About

Former Editor, now flitting back and forth as a freelancer. Originally from London and studied Zoology at the University of Reading, UK. Previous work includes having written for The Spark University Newspaper and the Wellcome Trust.

Articles by Dani Bancroft

biogeneration capital ventures finance money fund biotech medtech

News and Trends 5 Jul 2016

The Fund behind the ‘Biggest Private Exit Ever’ to Raise another €50M

BioGeneration Ventures has had its first close of a new venture capital fund, ‘BioGeneration Capital Fund III’, for novel diagnostic, medtech and therapeutic biotechs in Europe. BioGeneration Ventures (BGV) is based in Naarden (Netherlands) and manages funds investing in Netherlands, Belgium and Germany. Some of its biotech porfolio companies have included Dezima Pharma (acquired by Amgen from […]

July 5, 2016 - 2 minutesmins - By Dani Bancroft

deskgen desktop genetics biotech labiotech refresh crispr

News and Trends 5 Jul 2016

“CRISPR is highly fragmented, with too many approaches. We bring it all together”

The problem with CRISPR, is that not many people are actually experts in the field, and there are only a select few who worked on it pre-2013. So how did this UK Startup make a big name for itself in field of the ‘Biotech Breakthrough of the Century’? Desktop Genetics is a startup founded in 2012 by three […]

July 5, 2016 - 4 minutesmins - By Dani Bancroft

cinfa amgen biosimilar biotech neutropenia chemotherapy

News and Trends 5 Jul 2016

Spanish Biotech gets New Milestone in Biosimilar Race with Amgen

The Spanish Cinfa Biotech’s race to compete with Amgen’s blockbuster for Chemotherapy-induced Neutropenia continues: the Neulasta biosimilar passes Phase I trials. Neulasta (pegfilgrastim) is a slightly longer acting version of Amgen’s other blockbuster Neupogen (the template for the first ever US approved biosimilar – from Novartis), the combined sales of which account for over 30% of Amgen’s income. […]

July 5, 2016 - 2 minutesmins - By Dani Bancroft

uk biohackathon cambridge cutec 2016 biohacking alpha brick

News and Trends 4 Jul 2016

What kind of Startups were born at the UK’s First Biohackathon?

Organised by the University of Cambridge Technology and Enterprise Club (a catchy ‘CUTEC’ for short), the Biohackathon was the first of its kind organised in the UK… With SynBio veterans such as Bento Bio (inventors of the ‘Lunch box sized Laboratory’ for hackers, schools and DIY enthusiasts), Synthace (which invented Antha – ‘the programming language of […]

July 4, 2016 - 5 minutesmins - By Dani Bancroft

bristol myers squibb immunooncology cancer opdivo psioxus

News and Trends 1 Jul 2016

BMS to combine Immuno-Oncology Blockbuster with Oxford Biotech

Oxfordshire based PsiOxus will team up with the Immuno-Oncology Giant, Bristol-Myers Squibb, to test the combinatorial effect of their blockbuster drug with an Oncolytic viral therapy in late-stage cancer patients. Together they will evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ Enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, in combination with Bristol-Myers Squibb’s Opdivo blockbuster (nivolumab), which […]

July 1, 2016 - 3 minutesmins - By Dani Bancroft

nash evotec biotech accellerate ellersbrook pharma liver steatohepatitis

News and Trends 30 Jun 2016

Germany joins the Biotech Front against a ‘Silent Epidemic’ of the Liver

The German life sciences investor, Ellersbrook, is putting millions into Evotec‘s drug discovery program. Together the two join a biotech industry hunt for a therapy against a metabolic liver disease (NASH) that affects 30% of adults worldwide. Ellersbrook is a life science focused investment firm owned by Herbert Stadler, a renowned biotech entrepreneur. It is now looking to accelerate […]

June 30, 2016 - 2 minutesmins - By Dani Bancroft

diabetes glucose chronic disease biotech pharma review

News and Trends 14 Jun 2016

Could this be the ‘Beginning of the end’ for Diabetes? Let’s Review.

Given the rates of diabetes reaching ‘epidemic proportions’, we figured it was time to have a better overview of biotech’s progress in the field. With some serious advances having been made in the treatment of the disease, we have to ask – how much further can biotech go in the treatment of diabetes? It is important […]

June 14, 2016 - 9 minutesmins - By Dani Bancroft

synbio synthetic biology paillasse deinove indiebio biohacking polack

News and Trends 13 Jun 2016

“A new generation of Bio-entrepreneurs is rising right now” – SynBio in Europe

Our SynBio panel had a really popular turn-out at Labiotech Refresh. Chaired by Cathal Garvey, the Program Director at IndieBio EU, we had some very diverse leaders in the field present, from Biohackers to the CEO of Biofuel giant, Deinove. Asides Cathal, on the panel we had Axel Polack, a General Partner at the Joint Polish […]

June 13, 2016 - 4 minutesmins - By Dani Bancroft

asco biotech morphosys cancer chicago 2016 researh pharma

News and Trends 9 Jun 2016

How was it inside the ‘World Most Important Cancer Meeting’ of the Year?

Every year by the end of May/beginning of June, up to 30,000 of healthcare professionals head to Chicago to discuss the most recent advancements in Cancer treatments. Here, the MorphoSys team, which included Claudia Gutjahr-Löser and Jochen Orlowski, give you a sneak-insiders look into one of the most essential Cancer conferences of the year… You can also […]

June 9, 2016 - 4 minutesmins - By Dani Bancroft

global bioenergies l oreal loreal cristal union isobutene cosmetic biofuel biotech

News and Trends 9 Jun 2016

Biotech, France and L’Oréal Team up for World First Biofuel Plant using Beets

The Investissements d’Avenir programme (a French government initiative) is providing €9M to both Global Bioenergies and IBN-One, as part of an project involving Cristal Union (the agro-business for Beet production) and L’Oréal (the cosmetics Giant). Together, they will develop the first commercial plant producing bio-sourced isobutene worldwide. Broken down into €5.7M for Global Bioenergies; €3.3M for IBN-One, the […]

June 9, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 7 Jun 2016

New Massive €250M Investment Fund Closed for European Biotech

Life Sciences Partners (LSP) has closed its new life sciences fund, ‘LSP5’. The fund surpassed its €152M target and reached the ‘hard cap’ of €250M, making it one of the largest life sciences funds in the EU. LSP is one of the oldest and most successful Biotech investors in Europe. It claims over 25% return […]

June 7, 2016 - 2 minutesmins - By Dani Bancroft

XenoTech sekisui ketonozole biotech cro clinical trials transporters drug pharmacokinetcis

News and Trends 7 Jun 2016

Understand which transporters are involved in a drug’s absorption, distribution & excretion

How can you build the best case for a new drug application to the regulatory agencies? Preclinical studies are a crucial part in determining the pharmacokinetics of a drug – and more specifically how it is going to interact with drug transporters. So reaching out to the leading provider and consultant in this area (with strong […]

June 7, 2016 - 4 minutesmins - By Dani Bancroft

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Dani Bancroft

About

Articles by Dani Bancroft

The Fund behind the ‘Biggest Private Exit Ever’ to Raise another €50M

“CRISPR is highly fragmented, with too many approaches. We bring it all together”

Spanish Biotech gets New Milestone in Biosimilar Race with Amgen

What kind of Startups were born at the UK’s First Biohackathon?

BMS to combine Immuno-Oncology Blockbuster with Oxford Biotech

Germany joins the Biotech Front against a ‘Silent Epidemic’ of the Liver

Could this be the ‘Beginning of the end’ for Diabetes? Let’s Review.

“A new generation of Bio-entrepreneurs is rising right now” – SynBio in Europe

How was it inside the ‘World Most Important Cancer Meeting’ of the Year?

Biotech, France and L’Oréal Team up for World First Biofuel Plant using Beets

New Massive €250M Investment Fund Closed for European Biotech

Understand which transporters are involved in a drug’s absorption, distribution & excretion

Subscribe to our newsletter to get the latest biotech news!